Uchiyama Holdings Co Ltd

Uchiyama Holdings Co Ltd has a liquidity position that is currently medium, with a current ratio of 1.62, indicating the company can cover its short-term liabilities with its short-term assets. The company holds JPY 10,758,237,000 in cash and equivalents, but this is offset by long-term debt of JPY 13,637,708,000, resulting in a negative net cash position. This suggests the company may need to rely on operating cash flow or external financing to service its debt obligations.

The company's profitability is underperforming relative to industry norms, with a return on equity (ROE) of -1.29% and a return on assets (ROA) of -0.51%. These negative returns indicate that the company is not generating sufficient returns to cover its cost of capital, which is a concern for investors. The operating loss of JPY 294,567,000 and net loss of JPY 158,982,000 further underscore the company's financial challenges.

Uchiyama Holdings Co Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to sector-specific risks, such as regulatory changes or shifts in demand for biotechnology services.

The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The operating cash flow of JPY 2,002,765,000 is a positive sign, but it is not sufficient to offset the net loss or the capital expenditure of JPY 896,404,000. The company's capital structure is heavily leveraged, with a debt-to-equity ratio of 1.1, which increases financial risk and may limit its ability to invest in growth opportunities.

The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position is a key flag, suggesting potential liquidity constraints. However, the low dilution risk implies that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders. The company's recent financial performance and capital structure suggest that it may need to manage its debt more effectively to improve its financial health.

Recent events, including the company's financial performance and capital structure, have been disclosed in its latest financial statements. The company's operating cash flow and capital expenditure figures indicate that it is investing in its operations, but the net loss and negative ROE suggest that these investments are not yet generating returns. The company's management will need to address these issues to improve its financial performance and reduce its financial risk.

Net income surged 858.9% year-over-year to JPY 2.05 billion in fiscal 2025, marking a significant profitability turnaround.

Free cash flow turned positive to JPY 1.37 billion in fiscal 2025, a 694.6% increase from the prior year.

Revenue demonstrated consistent growth with a 5.2% compound annual growth rate over the last four fiscal years.

Long-term debt decreased to JPY 12.73 billion in fiscal 2025, indicating a reduction in leverage from previous peaks.

The company faces low dilution risk, suggesting current equity structure stability despite recent financial volatility.

The company carries high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing.

Debt-to-equity ratio stands at 1.1, placing it in the bottom quartile compared to the healthcare facilities cohort median of 0.32.

Return on equity is negative at -1.29%, underperforming the cohort median of 4.56% and failing to generate shareholder value.

Revenue ¥7.43B, +1,3% YoY; Operating income −57,3% YoY.

• ▍Revenue ¥7.43B, +1,3% YoY
• ▍Operating income −57,3% YoY
• ▍Net income +47,4% YoY
• ▍Net margin 1.5%

Revenue ¥7.50B, +2,8% YoY; Operating income +284,1% YoY.

• ▍Revenue ¥7.50B, +2,8% YoY
• ▍Operating income +284,1% YoY
• ▍Net income −23,9% YoY
• ▍Net margin 2.9%

Revenue ¥7.33B, +1,8% YoY; Operating income +224,9% YoY.

• ▍Revenue ¥7.33B, +1,8% YoY
• ▍Operating income +224,9% YoY
• ▍Net income +375,5% YoY
• ▍Net margin 2.6%

Revenue ¥7.26B, −0,0% YoY; Operating income −26,9% YoY.

• ▍Revenue ¥7.26B, −0,0% YoY
• ▍Operating income −26,9% YoY
• ▍Net income +1 140,1% YoY
• ▍Net margin 22.8%

Revenue ¥7.34B; Operating income ¥134.9M.

• ▍Revenue ¥7.34B
• ▍Operating income ¥134.9M
• ▍Net margin 1.0%

Revenue ¥7.30B; Operating income ¥53.8M.

• ▍Revenue ¥7.30B
• ▍Operating income ¥53.8M
• ▍Net margin 3.9%

Revenue ¥7.20B; Operating income ¥72.2M.

• ▍Revenue ¥7.20B
• ▍Operating income ¥72.2M
• ▍Net margin 0.6%

Revenue ¥7.27B; Operating income -¥294.6M.

• ▍Revenue ¥7.27B
• ▍Operating income -¥294.6M
• ▍Net margin -2.2%

Revenue ¥29.11B, +0,9% YoY; Operating income −221,5% YoY.

• ▍Revenue ¥29.11B, +0,9% YoY
• ▍Operating income −221,5% YoY
• ▍Net income +858,9% YoY
• ▍Free cash flow +694,6% YoY
• ▍Net margin 7.0%

Revenue ¥28.84B, +7,2% YoY; Operating income +111,4% YoY.

• ▍Revenue ¥28.84B, +7,2% YoY
• ▍Operating income +111,4% YoY
• ▍Net income +153,4% YoY
• ▍Free cash flow +90,3% YoY
• ▍Net margin 0.7%

Revenue ¥26.91B, +7,8% YoY; Operating income −60,8% YoY.

• ▍Revenue ¥26.91B, +7,8% YoY
• ▍Operating income −60,8% YoY
• ▍Net income +38,4% YoY
• ▍Free cash flow −77,8% YoY
• ▍Net margin -1.5%

Revenue ¥24.96B, +4,9% YoY; Operating income +71,0% YoY.

• ▍Revenue ¥24.96B, +4,9% YoY
• ▍Operating income +71,0% YoY
• ▍Net income +70,9% YoY
• ▍Free cash flow +60,7% YoY
• ▍Net margin -2.6%